Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance-Reference-Cited by-同舟云学术

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

Published:2020-07-28 Issue:4 Volume:15 Page:449-466
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Raschi Emanuel^ORCID,Gatti Milo,Gelsomino Francesco,Ardizzoni Andrea,Poluzzi Elisabetta,De Ponti Fabrizio

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-020-00738-6.pdf

Reference102 articles.

1. Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235–47.

2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.

3. Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf. 2019;42:281–94.

4. Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20:e54–64.

5. Barquìn-Garcìa A, Molina-Cerrillo J, Garrido P, Garcia-Palos D, Carrato A, Onso-Gordoa T. New oncologic emergencies: what is there to know about inmunotherapy and its potential side effects? Eur J Intern Med. 2019;66:1–8.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC;Immunotherapy;2024-09-13

2. A new classification of upper gastrointestinal toxicity induced by immunotherapy: from endoscopic and pathological insights to clinical management;ESMO Gastrointestinal Oncology;2024-09

4. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports;Seminars in Arthritis and Rheumatism;2024-08

5. Immune checkpoint inhibitors-induced diabetes mellitus (review);Endocrine;2024-07-03